Plan Ahead(TM) Test Offers Most Accurate Measurement of Women's Ovarian
ATLANTA, Jan. 21 /PRNewswire/ -- Georgia Reproductive Specialists (GRS) today announced it will be the first IVF center in the southeast to offer the Repromedix Plan Ahead(TM) test, an innovative blood test that provides an assessment of a woman's egg supply by combining multiple factors, including the measurement of ovary-related hormones AMH, Inhibin B, and FSH. The window of opportunity for a woman to have children by natural conception is dependent upon an adequate supply of eggs, which inevitably declines as a woman ages and her "biological clock ticks." Plan Ahead enables a woman to compare her estimated egg supply with the normal range expected for women of the same age.
The Plan Ahead Report provides valuable directional information about which women planning to have children after their late twenties should seek further advice from fertility experts to help ensure that those women with faster biological clocks can have the families they were hoping for.
"GRS has always incorporated the latest assisted reproductive technologies (ART) into our treatment plans to give our patients the best chance possible of having a baby, said Mark Perloe, M.D., Medical Director of Georgia Reproductive Specialists. "We strive to provide our patients with the most advanced testing and treatment options, so it is most appropriate that GRS is the first IVF center in the Southeast to offer the Plan Ahead test."
As women age, their fertility naturally declines, with increasingly fewer eggs available for fertilization. "With so many women delaying pregnancy until their 30s and 40s, women urgently need an accurate assessment of their egg supply," said Dr. Perloe. "And while we know that on average ovarian reserve begins a more rapid decline after age 35, it varies among women of the same age. The Plan Ahead test will provide women with the individual assessment of their own ovarian reserve to help them make more informed decisions about when to have a child. We're pleased to be in the vanguard of this critical new test."
"The Plan Ahead test represents an extraordinary advance in fertility diagnostics compared to what has been readily available to the general population," said Dr. Benjamin Leader, Chief Medical Officer of Repromedix Corp. "Many fertility experts view the gold standard of egg supply measurement to be the number of eggs obtained through egg retrieval, an expensive procedure reserved for specialty fertility clinics involving hormone injections and a minimally invasive procedure. The Plan Ahead test offers similar information to the general public via a simple blood test."
Repromedix Corp., the Plan Ahead test co-developer and leading national diagnostic laboratory for fertility testing, chose GRS to be one of a select number of IVF centers to debut the test. Repromedix will expand the Plan Ahead test launch to major markets across the United States throughout 2008.
Plan Ahead is now available to women in the greater Atlanta area, and women interested in the Plan Ahead test can purchase a test online at http://www.planaheadtest.com/us or at Georgia Reproductive Specialists, where they can also have their blood drawn. The blood sample is sent to Repromedix, whose lab performs the advanced testing and submits the report and recommendations to the patient's physician. The cost of the Plan Ahead test is $350. Women interested in learning more about Plan Ahead, should visit: http://www.planaheadtest.com/us.
About Georgia Reproductive Specialists (http://www.ivf.com)
Georgia Reproductive Specialists (GRS), founded in 2000, applies medical science's most advanced fertility technologies to provide the highest standards of patient-centered, reproductive healthcare. The staff at GRS is focused on providing individualized, innovative solutions for reproductive challenges and infertility, specializing in in vitro fertilization, intracytoplasmic sperm injection and other assisted reproductive technologies.
About Repromedix (http://www.repromedix.com)
Repromedix is the leading national diagnostic laboratory for fertility testing and offers a multifaceted approach to clinical fertility testing that encompasses many medical disciplines including endocrinology, immunology and genetics. Repromedix offers the most comprehensive suite of advanced diagnostic tests that provide valuable information regarding the complex problems of reproductive failure. Since its inception in 1993, the company has assisted more than 45,000 patients by performing over 100,000 diagnostic tests for recurrent pregnancy loss, premature ovarian failure, male infertility, and unexplained infertility. Repromedix is a portfolio company of Brook Venture Partners, Ironwood Capital Management, and Brooke Private Equity Advisors.
Contact: Lisa Hester, Rountree Group
email@example.com Available Topic Expert(s): For information on the listed expert(s), click appropriate link. Julie Dennehy https://profnet.prnewswire.com/Subscriber/ExpertProfile.aspx?ei=60399
Copyright©2008 PR Newswire.
All rights reserved